Completed PHASE3 INTERVENTIONAL 2-arm NCT00093262

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2) (ESCAPE-2)

Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Sponsor: The Medicines Company

Updated 6 times since 2017 Last updated: May 7, 2014 Started: Dec 31, 2003 Primary completion: Oct 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypertension, this trial is completed. The trial is conducted by The Medicines Company and has accumulated 6 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Blue Island, United States , Charlotte, United States , Glencoe, United States , Houston, United States , Kansas City, United States , Los Angeles, United States , Milwaukee, United States , Missoula, United States , Mobile, United States and 4 more locations